Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry ...

Cybin (NYSE American: CYBN) (NEO: CYBN) , a clinical-stage neuropsychiatry company, summarized its 2024 accomplishments and detailed upcoming 2025 m ...

Johnson & Johnson has agreed to take over Intra-Cellular Therapies in a deal worth up to $14.6 billion – the second biopharma ...

Cybin (NYSE Americ a n: CYBN) (NEO: CYBN) a clinical-stage neuropsychiatry company, announced that CEO Doug Drysdale will join a fireside chat at th ...

The Center for Nanophase Materials Sciences (CNMS) at Oak Ridge National Laboratory (ORNL) offers the national and international user community access to staff ...

The new data showed that 75% of patients who had received two 16 mg doses of deuterated psilocybin analogue CYB003 – given three weeks apart and on top of current antidepressant drugs – were ...

After hours: January 10 at 7:53:58 p.m. EST ...

The popularity of psilocybin is fast-rising, with an estimated 8 million American adults using it in 2023.  The percentage of US adults who have used psilocybin at least once in their lifetime, ...